Decorative image for Follow Our Progress page banner

Follow Our Progress

Presentations Uncategorized

Safety, Biomarker Responses, and Preliminary Efficacy Following a Single Intrathecal Dose of RAG-17, a Novel siRNA Therapeutic for SOD1-ALS: Results from an Ongoing Phase I/II Study (Poster)

By Ractigen04/19/2026June 8th, 2026No Comments

PUBLICATIONS & PRESENTATIONS

04/19/26

Safety, Biomarker Responses, and Preliminary Efficacy Following a Single Intrathecal Dose of RAG-17, a Novel siRNA Therapeutic for SOD1-ALS: Results from an Ongoing Phase I/II Study (Poster)

Event: 2026 American Academy of Neurology (AAN) Annual Meeting（Chicago）

View News: Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain